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Lung cancer remains a leading cause of disease globally with smoking being the largest 
single cause. Phase I enzymes including cytochrome P450 family 1, subfamily A, 
polypeptide 1 (CYP1A1), are involved in the activation of carcinogens such as polycyclic 
aromatic hydrocarbons (PAHs) to reactive intermediates, which are capable of binding 
covalently to DNA to form DNA adducts, potentially initiating the carcinogenic process. The 
present study aimed to investigate the association of CYP1A1 polymorphisms and haplotypes 
with lung cancer risk. 
We performed a case-control study of 1040 non-small cell lung cancer (NSCLC) cases and 
784 controls on three variants, CYP1A1*2A (rs4646903 3801T>C), CYP1A1*2C (rs1048943 
2455A>G Ile462Val (Exon 7)), and CYP1A1*4 (rs1799814 2453C>A Thr461Asn (Exon 7)) 
using PCR-RFLP methods.  
CYP1A1*2A and CYP1A1*2C variants were significantly over-represented in NSCLC cases 
compared with controls whilst the CYP1A1*4 variant was under-represented. CYP1A1 
haplotypes (allele order: CYP1A1*4-CYP1A1*2C-CYP1A1*2A) C-G-C and C-G-T were 
associated with an increased risk of lung cancer, while A-A-T was associated with decreased 
lung cancer risk in this population.  
This study identifies risk haplotypes for CYP1A1 in NSCLC and confirms that CYP1A1 
polymorphisms are a minor risk factor for NSCLC. 




Lung cancer is a leading cause of cancer death internationally, with smoking being the largest 
single cause. Smoking is responsible for 85-90% of lung cancers [1] yet fewer than 20% of 
life-long smokers will develop lung cancer suggesting that other factors including genetics 
may play a role [1]. Phase I enzymes (mainly cytochrome P450) metabolically activate 
carcinogens such as polycyclic aromatic hydrocarbons (PAHs) and N-nitrosamines to 
reactive intermediates [2]. These intermediates are capable of binding covalently to DNA to 
form DNA adducts, potentially initiating the carcinogenic process. Two functionally 
important non-synonymous polymorphisms have been described for the CYP1A1 gene, a base 
substitution at codon 462 in exon 7, resulting in an isoleucine to valine amino acid 
substitution (CYP1A1*2C; rs1048943 2455A>G Ile462Val (Exon 7)) and a point mutation 
(thymine/cytosine) at the Msp1 site in the 3’UTR (CYP1A1*2A; rs4646903 3801T>C) [3, 4]. 
A third polymorphism substituting threonine for asparagine (CYP1A1*4; rs1799814 
2453C>A Thr461Asn (Exon 7)) has also been reported two bases upstream of CYP1A1*2C, 
however its functional effects have yet to be fully elucidated. 
Ethnic differences have been reported in the distribution of CYP1A1*2C and CYPA1*2A 
genotypes in lung cancer subjects with few reports available for CYP1A1*4. An over-
representation of the valine allele (CYP1A1*2C) among lung cancer cases has been reported 
in Asian and Caucasian populations [5-7]. While relatively frequent in Asian populations 
(0.18-0.25) [8, 9] the valine allele is quite rare in Caucasian control populations occurring in 
approximately 7-13% of people [7, 10].  In a previous study, we did not show any interactive 
effects between CYP1A1*2C and polymorphisms of the Phase II enzymes GSTP1, GSTT1 or 
GSTM1. However, risk genotypes for MPO and CYP1A1*2C interacted to increase the 
overall risk of NSCLC (OR 2.88; 95%CI 1.70–5.00; P=0.001) [11]. Similarly, the 
CYP1A1*2A variant has been strongly associated with increased lung cancer risk in Asian 
populations especially in relation to tobacco smoking and in combination with 
polymorphisms of Phase II enzymes GSTM1 and GSTT1 [12, 13].  In contrast, studies in 
Caucasian populations have not clearly established an association between CYP1A1 
polymorphisms and increased lung cancer risk [14-19]. Relatively frequent incidences of 
CYP1A1*2A variants have been reported in Asian (39%) [20] and Caucasian control 
populations (18-23%) [14, 16, 21]. Conversely, few studies report population frequencies for 
CYP1A1*4 in lung cancer subjects.  Cascorbi et. al [6] has reported variant allele frequencies 
of 3% in Caucasian lung cancer cases and controls. In contrast Song et. al, detected no 
polymorphic sites in an Asian population [13] supporting similar polymorphism studies of 
Japanese liver subjects [10]. Similar frequencies (2-3%) have been observed in healthy 
Caucasian populations [22, 23].   A recent pooled analysis by Hung et al. [24] reported an 
increase in lung cancer susceptibility by more than two-fold for CYP1A1*2A and 
CYP1A1*2C in non-smokers. The authors suggested these polymorphisms may be implicated 
in lung carcinogenesis at low levels of tobacco exposure possibly in combination with phase 
II enzymes including GSTM1 [24], although this has not been replicated by other groups 
[21]. 
Many studies investigating the relationships between CYP1A1 polymorphisms and lung 
cancer have been limited by small sample numbers leading to a lack of statistical power. 
Pooled analyses to increase sample size have tried to address this issue. Conflicting results 
between groups may be due to population differences (i.e. ethnicity) or failure to control for 
other potential confounders including age and gender. CYP1A1 haplotype studies have 
potential to determine whether combinations of CYP1A1 (CYP1A1*2A, CYP1A1*2C, 
CYP1A1*4) together confer a greater risk of lung cancer than single polymorphisms. One 
recent study of 200 case-matched controls from an Indian population, showed that only one 
haplotype (C-G-C) was significantly associated with increased lung cancer risk, although the 
 
 
study was limited by its small sample numbers [3]. Few haplotype association studies for 
CYP1A1 have been conducted in a Caucasian population.  A study by Han et al [25] 
investigated the genotype frequencies of 13 SNPs found in the promoter region of CYP1A1 
in 21 Caucasian individuals. Subsequent functional studies identified two CYP1A1 
haplotypes (2923C<T-2875G<A-3777T<G and 2923C<T-3777T<G-4553G<A) 
demonstrating moderate increases in basal activity compared with the wildtype CYP1A1 
constructs (1.38 and 1.50 respectively P<0.05). These were considered unlikely to be of 
functional significance considering the magnitude of differed CYP1A1 expression in 
response to benzo[a]pyrene and cigarette smoke extract [25].   
To further investigate the role of CYP1A1 polymorphism variation (CYP1A1*2C, 
CYP1A1*2A and CYP1A1*4) in lung cancer risk we performed CYP1A1 haplotype analyses 




Materials and Methods 
Study population 
This study population has been described previously [11, 26]. Cases were subjects with 
confirmed primary lung cancer treated at The Prince Charles Hospital between 1980 and 
2007 (n = 1040). Controls consisted of subjects with chronic obstructive pulmonary disease 
(COPD) treated at the same hospital (n=506) or healthy smokers (n = 278) who, at the time of 
recruitment to this study, did not have a doctor-diagnosis of lung cancer. The ethnicity of the 
study population was >99% Caucasian. The study was approved by the Ethics Committee at 
The Prince Charles Hospital. Cases and controls gave informed written consent for use of 
resected lung tissue or peripheral blood. Demographics for cases and controls were checked 
by a research nurse or the treating physician against patient medical charts or the hospital 
lung cancer database (Table 1). 
Sample Preparation and Genotyping 
DNA from cases diagnosed with NSCLC was extracted from peripheral blood or resected 
cryopreserved normal lung tissue as described previously [26]. Cases and controls from our 
previous study of CYP1A1*2C were included [11, 26].  DNA from control subjects was 
extracted from peripheral blood. In 592 cases, DNA was extracted from more than one source 
(blood-lymphocyte and fresh-frozen normal lung tissue). In these cases both sources were 
genotyped with identical results in all cases, reinforcing the reproducibility of our methods. 
PCR-based restriction fragment length polymorphism (RFLP) methods were used to analyse 
CYP1A1*2A [27] and CYP1A1*4 [6] polymorphisms.  Approximately 10% of samples were 
randomly selected for repeat genotyping by PCR-RFLP to test reproducibility.  
 
DNA sequencing and single base extension genotyping 
To confirm accuracy of PCR-RFLP methods, each polymorphism had two representative 
samples per genotype confirmed by DNA sequencing. Samples were purified using the 
Wizard PCR Cleanup and Gel extraction kit (Promega, Madison, USA) and sequenced at the 
Australian Genome Research Facility (AGRF, Brisbane, Australia) for DNA sequencing 
using BigDye Terminator V3.1 chemistry (Applied Biosystems, California, USA). 
Sequencing primers were identical to those used in PCR amplification. Sequences were 
visualised using Chromas V1.4 (Conor McCarthy, School of Biomolecular and Physical 
Sciences, Griffith University, Brisbane, Australia).  
In addition, we also used an independent genotyping method, iPLEX single base extension, to 
genotype a subset (89%) of subjects genotyped by PCR-RFLP methods. All experiments 
were performed by the AGRF. Briefly genomic DNA was amplified using primers with 10-
mer tags, designed to amplify a 75-150bp amplicon. Following this, shrimp alkaline 
phosphatase (SAP) was added to each reaction to remove any unincorporated dNTPs by 
cleavage of phosphates from dNTP groups. An iPLEX reaction master mix consisting of 
primer, enzyme, buffer and mass-modified nucleotides was then added and samples placed in 
a thermocycler to allow addition of nucleotides to the polymorphic site, producing allele 
specific base extension products of differing sizes. Products were then run on a MALDI-TOF 
mass spectrometer to determine product size. 
 
Statistical Analysis 
Distributions of genotypes and demographic variables were compared between cases and 
controls using chi-square tests for categorical outcome variables and two-sided t-tests for 
continuous outcome variables. Odds ratios (OR) and 95% confidence intervals (CI) were 
estimated to measure the association between lung cancer and genotype/haplotype frequency. 
Standard chi-square statistics were used to determine whether the three CYP1A1 variants 
were in Hardy-Weinberg equilibrium. All statistical analyses for genotypes were performed 
 
 
using the SPSS software package (Version 13.0 for Windows: SPSS Inc., Chicago, IL, USA). 
Haplotype analyses (haplotype frequency estimations and linkage disequilibrium) were 
carried out using Haploview Linkage software (Version 4.0, 
http://www.broad.mit.edu/edu/mpg/haploview [28]). A P value less than 0.05 (two-tailed) 
was considered statistically significant. Power calculations to evaluate our ability to detect 
associations between NSCLC and CYP1A1 variants among our study population were 
determined using α = 0.05 and 80% power.  This study had the power to detect an odds ratio 
of 1.39, 1.48 and 1.69 for the variant alleles of CYP1A1*2A, CYP1A1*4 and CYP1A1*2C 
respectively with 80% confidence at α = 0.05. 
Results: 
Participant characteristics 
To ensure that observed effects between cases and controls were due to genotype frequency 
and not other potential confounding factors such as age, smoking history or gender, we 
compared mean and frequency distributions between cases and controls (Table 1). Mean age 
differed significantly between cases and controls (P<0.001) with controls being slightly 
younger. In contrast, there were no significant differences in gender distribution (P=0.81) or 
pack-years smoked (P=0.47), excluding these factors as potential study confounders. The 
majority of NSCLC cases were adenocarcinoma or squamous cell carcinoma histological 
subtypes (39% and 36%, respectively).  
To confirm the validity of combining COPD subjects and healthy smokers to form one 
control group as we have done previously [26], we used chi-square tests to investigate 
whether there were significant differences in genotype frequency between the two groups.  
We observed no significant difference in variant frequency between COPD and healthy 
smokers (P>0.05, data not shown) validating our decision to combine these two subgroups.  
PCR-RFLP 
Genotype frequencies for all three variants, determined by PCR-RFLP methods, are detailed 
in Table 3. Variant allele frequencies were low in the control population for all SNPs. The 
minor allele frequencies for combined cases and controls were 4.6%, 4.5% and 11.4% for 
CYP1A1*4, CYP1A1*2C and CYP1A1*2A respectively. As less than five samples were 
classified as homozygous for the variant allele in either cases or controls for CYP1A1*2C 
CYP1A1*4, homozygous variants were combined with heterozygous genotypes for statistical 
analysis (Table 4). In this study, genotypes containing the variant allele of CYP1A1*2A 
occurred in 17.6% of the control population, CYP1A1*4 in 11% and CYP1A1*2C in 5.5%. 
These values were in relative agreement with previous studies of Caucasian populations 
(CYP1A1*2A 18 – 23%; CYP1A1*4 2 – 3%, CYP1A1*2C 9 – 10%) [14, 16, 21-23]. In this 
study population, genotype frequencies of CYP1A1*2A and CYP1A1*4 were in Hardy-
Weinberg Equilibrium for cases and controls, however CYP1A1*2C was not (Table 2). DNA 
Sanger sequencing of two samples per genotype were performed for each polymorphism to 
confirm the accuracy of PCR-RFLP assays.  
From the PCR-RFLP data, we observed that subjects carrying the CYP1A1*2A variant were 
overrepresented in NSCLC cases compared with controls (TT versus CT/CC: OR 1.43, 
95%CI 1.35-1.51, P=0.003). We also observed a decreased risk of NSCLC for those with the 
CYP1A1*4 variant (CC versus CA/AA; OR 0.64 95% CI 0.64-0.62; P=0.005). The wildtype 
genotype (CC) was slightly over-represented in cases versus controls (92.8% versus 89%). 
Data from our previous study on CYP1A1*2C was included in this study. The variant allele 
was associated with a greater than two-fold increase in the risk of lung cancer.  
To investigate associations between the three polymorphisms, haplotype analyses were 
performed to determine whether combined polymorphisms conferred a greater lung cancer 
risk. Five possible haplotypes were identified amongst cases and the larger control group: 
where the haplotype C-A-T was considered to be the wildtype (haplotype order = CYP1A1*4-
 
 
CYP1A1*2C-CYP1A1*2A). The frequencies of C-A-T, C-A-C, A-A-T, C-G-C and C-G-T are 
presented in Table 4.  Two haplotypes were significantly over-represented in NSCLC versus 
controls, C-G-C (4.1% versus 2.4%, P=0.0038; OR 1.76, 95% CI 1.19-2.60) and C-G-T 
(1.4% versus 0.4%, P=0.0026; OR 3.26, 95% CI 1.46-7.28). Conversely, A-A-T was 
significantly under-represented in cases versus controls (3.4% versus 5.4%, P=0.0014; OR 
0.62, 95% CI 0.45-0.86). C-A-C showed a general increase in lung cancer risk, though this 
did not reach statistical significance (8.5% versus 6.9%, P=0.0747; OR 1.25, 95% CI 0.98-
1.60). We found CYP1A1*2A and CYP1A1*2C were in linkage disequilibrium (D’=0.749; 
LOD = 66.5; r2 =0.207; 95% CI = 0.67-0.81) but not CYP1A1*4 and CYP1A1*2C (D’=0.01; 
LOD=0; r2=0; 95% CI = 0.01-0.696) or CYP1A1*4 and CYP1A1*2A (D’=0.582; LOD = 
1.21; r2 = 0.0020; 95% CI =0.17-0.82).  
Single base extension genotyping 
As a secondary method of confirming PCR accuracy and to address the issue of Hardy-
Weinberg disequilibrium, we used single base extension genotyping methods (iPLEX, 
AGRF, Brisbane, Australia) to genotype cases and controls. We were able to successfully re-
genotype 89% of cases and controls with iPLEX, with failure rates of 3-5% for the three 
genotypes. Tables 3 and 4 illustrate the sample numbers, genotype frequencies and haplotype 
frequencies observed using iPLEX. All variants were in Hardy-Weinberg equilibrium for our 
control population (Table 2) with two of three variants in Hardy-Weinberg equilibrium for 
cases (Table 2). 
We observed similar genotype frequencies for CYP1A1*2C, CYP1A1*4 and CYP1A1*2A, 
although relatively fewer variant homozygotes were observed for CYP1A1*4 (Controls - 5 for 
PCR-RFLP vs 0 for iPLEX). Observed associations between CYP1A1 polymorphisms and 
lung cancer risk remained consistent, with subjects carrying the CYP1A1*2A variant 
overrepresented in NSCLC cases compared to controls (TT versus CT/CC: OR 1.43, 95% CI 
1.35-1.52, P=0.005), and carriers of the CYP1A1*4 variant under-represented in NSCLC 
cases (CC versus CA/AA; OR 0.66, 95% CI 0.67-0.66; P=0.026). Carriers of the CYP1A1*2C 
variant were also associated with elevated lung cancer risk (AA versus AG/GG: OR 1.83; 
95% CI 1.57-2.12, P=0.002), consistent with our previous findings. While our findings from 
PCR-RFLP remain consistent, we observed a decrease in statistical significance possibly due 
to the small decrease in sample number genotyped by iPLEX.  
To ensure that our haplotype findings from PCR-RFLP still remained consistent, we also 
performed new haplotype analyses on the iPLEX data. Only samples with iPLEX genotype 
data for all three polymorphisms were included in these analyses. We observed four possible 
haplotypes amongst cases and controls (haplotype order = CYP1A1*4-CYP1A1*2C-
CYP1A1*2A; C-A–T, C-A-C, C-G-C, A-A-T; Table 4) where C-A-T was considered to be the 
wildtype. We did not observe any of the C-G-T haplotype in this group. Two of these 
haplotypes were significantly associated with either increased (C-G-C; 5.3% versus 3.0%, 
P=0.0023) or decreased lung cancer risk (A-A-T, 3.4% versus 4.8%, P=0.037) with C-A-C 
showing a trend towards increased lung cancer risk (8.5% versus 6.7%, P=0.063). These risk 
haplotypes were also identified in our PCR-RFLP haplotype analyses. CYP1A1*2A and 
CYP1A1*2C remained in linkage disequilibrium (D’=1.0; LOD = 98.17; r2 =0.324; 95% CI = 
0.97-1.00) with CYP1A1*4 and CYP1A1*2C (D’=0.991; LOD=0.67; r2=0.002; 95% CI = 
0.11-0.98) and CYP1A1*4 and CYP1A1*2A (D’=1.0; LOD = 2.76; r2 = 0.006; 95% CI 
=0..48-1.00) not exhibiting disequilibrium, as observed in our PCR-RFLP findings.  
 
Discussion 
We have previously shown that carriers with the valine allele CYP1A1*2C (Ile/Val or 
Val/Val genotypes) are significantly overrepresented in NSCLC compared to controls (OR 
1.9; 95% CI 1.20–2.90; P=0.005), especially in women, those aged <64 years and those with 
 
 
<46 pack years of tobacco exposure [26]. We have previously shown that the CYP1A1*2C 
variant in combination with the MPO risk allele confers a significantly increased risk of 
NSCLC (OR 2.88; 95% CI 1.70–5.00; P<0.0001) [11]. In this report, we present the 
genotype and haplotype frequencies of two additional CYP1A1 polymorphisms in relation to 
lung cancer risk. Our data indicates an association between CYP1A1*2A and lung cancer risk 
and supports a recent pooled analysis of 2451 lung cancers and 3358 controls which showed 
a clear association between the homozygous CYP1A1*2A allele (CC) and lung cancer risk in 
Caucasians (age- and gender-adjusted OR 2.36; 95% CI 1.16-4.81) [15]. Although a meta-
analysis by Houlston et al., provided little support for variations of CYP1A1 involvement in 
lung cancer risk [29], a recent review investigating the role of polymorphisms in candidate 
genes for 18 different cancer sites, reported an increased risk of lung cancer for carriers of the 
CYP1A1*2A variant in Caucasian populations (OR 2.36; 95% 1.16–4.81; P=0.018) in 
addition to variants of CYP1A1*2C in Asian populations (OR 1.61; 95% CI 1.24–2.08; 
P=0.0003) [30]. Associations between CYP1A1 variations and lung cancer risk have also 
been observed in never-smokers with lung cancer [24, 31].  
CYP1A1*2A and CYP1A1*2C have been reported to be in linkage disequilibrium in 
Caucasian [18] and Asian populations [27] although not in people of African descent [32]. 
Linkage disequilibrium can be influenced by a variety of factors including genetic linkage, 
recombination, mutation rates, random drift, non-random mating and population structure. In 
this study, CYP1A1*2A and CYP1A1*2C were in linkage disequilibrium confirming reports 
from previous studies [18]. Conversely, like Cascorbi et. al, we did not observe evidence of 
linkage disequilibrium between CYP1A1*2C and CYP1A1*4 [6]. This may be due to the 
close proximity of the two variants (only one base pair separates the two polymorphic sites) 
decreasing the rate of recombination.  
The function of CYP1A1*4 has not been clearly established, although it has been suggested 
that it has the greatest enzymatic efficiency amongst all of the CYP1A1 polymorphisms [33]. 
In the present study, we identified very few homozygous variants in cases or controls for 
CYP1A1*4, limiting our ability to draw strong conclusions for a Caucasian population. 
However, we did observe a general decrease in frequency of heterozygotes in this study 
population compared to controls. Others have reported no clear association between lung 
cancer risk and CYP1A1*4 [3]. 
Very few haplotype analyses studying the interactions between CYP1A1*2A, CYP1A1*2C 
and CYP1A1*4 have been performed in a population of Caucasian lung cancer subjects. A 
recent pooled analysis studying interactions between CYP1A1 polymorphisms and 
GSTM1/GSTT1 in an Asian population, identified G-T and A-C haplotypes as being 
associated with lung cancer risk compared to A-T (OR 3.41; 95% CI 1.78-6.53 and OR 1.39; 
95% CI 1.12-1.71, respectively) [34]. Among our population, the haplotypes (allele order: 
CYP1A1*4-CYP1A1*2C-CYP1A1*2A) C-G-C and C-G-T were associated with an increased 
risk of lung cancer while A-A-T was associated with a decreased risk. In an Indian population, 
a four-fold increased lung cancer risk (HR 3.90, 95% CI 1.00–5.10, P=0.025) for the  C-G-C 
haplotype [3] was shown suggesting that this haplotype may be an important risk factor for 
NSCLC. Although the C-A-C haplotype has been associated with higher enzymatic activity 
and decreased cancer risk in prostate cancer [35], Shah et al [3], showed a trend for increased 
lung cancer risk although this did not reach statistical significance. The differences observed 
may be due to tumour type, gene expression or functional role of CYP1A1. For example, in 
addition to detoxification of carcinogens, CYP1A1 also has a role in the oxidative 
metabolism of estrogens [36] which have been implicated in the aetiology of prostate cancer 
[37, 38]. Chang et al, suggested that in prostate cancer, CYP1A1’s role of oestrogen 
metabolism may be more important than carcinogen detoxification [35]. Therefore, it is 
 
 
possible that the role of CYP1A1 differs between cancer types resulting in haplotype 
associations that vary according to tumour origin.  
Interpretation of our data from this study are curtailed by the low frequency of some variant 
genotypes (for instance, we observed very few A/A genotypes for CYP1A1*4) limiting our 
ability to draw statistically valid conclusions. Subjects in our control group also have the 
potential to develop lung cancer in the future: a source of misclassification bias. One of the 
polymorphisms, CYP1A1*2C was not in Hardy-Weinberg equilibrium (HWE) in either 
controls or cases for PCR-RFLP but was in HWE for iPLEX. In addition, while CYP1A1*2A 
was in HWE using PCR-RFLP, it was out of HWE via iPLEX for NSCLC subjects. This may 
be due to chance (from the selection of a large subset of the original samples), decreased 
sensitivity from iPLEX due to differences in sample concentration (Sequenom – 10 ng/ul; 
PCR-RFLP – 10-40 ng/ul as determined by gel estimation techniques), non-random 
population (highly unlikely), or a possible association with NSCLC risk. In addition, 
CYP1A1*4 and CYP1A1*2C are separated by only one nucleotide on exon 7 raising the 
possibility that misclassifications could occur. In this study, we tried to overcome this by 
employing published assays using enzymes that selectively digest each polymorphism 
irrespective of the neighbouring polymorphism, thereby decreasing the risk of 
misclassification bias. Finally, this study evaluated three commonly studied CYP1A1 
variants, however, it is possible that other SNPs may be in linkage disequilibrium with these 
variants, and may also be instrumental in determining lung cancer risk. 
Technical validation of our PCR-RFLP method by iPLEX confirmed our observed 
associations for all CYP1A1 polymorphisms. We observed similar genotype frequencies for 
CYP1A1*2C, CYP1A1*4 and CYP1A1*2A in both case and control populations. Haplotype 
analyses also confirmed association of haplotypes A-A-T and C-G-C with decreased and 
increased lung cancer risk respectively. We did not observe any of the C-G-T haplotype in 
these analyses and could not confirm association with lung cancer risk. Despite the 
significance of these results decreasing in the iPLEX cohort, we were still able to confirm the 
observations obtained using PCR-RFLP, increasing our confidence in the reproducibility of 
genotyping techniques. Due to our high reproducibility rate, we are confident that these 
associations are valid and support a role for CYP1A1 polymorphisms in altering lung cancer 
risk. 
In conclusion, the results of the present study confirm that CYP1A1 polymorphisms are a 
minor risk factor for NSCLC.  While several studies have confirmed associations between 
these polymorphisms and lung cancer risk in the past, few have explored linkage effects 
between the three different CYP1A1 polymorphisms in a Caucasian population. To the 
authors’ knowledge, this is the first study to show that haplotypes C-G-C, C-G-T and A-A-T 
are strongly associated with lung cancer risk in Caucasians. Identification of these haplotypes 
may assist in risk stratification, early detection and improvement of current treatment options 
for subjects with lung cancer.  Larger studies are required to explore these risk CYP1A1 
haplotypes further.  
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N  1040 784  
Genderc Male 710 (68%) 531 (68%) 0.807 
 Female 330 (32%) 253 (32%)  
Age Mean (SD)  65.7 (10) 63.1 (12.7) <0.0001 
 Range  32-92  19-93  
Pack-yearsc,d Mean (SD) 48 (35.1) 49.1 (33.5) 0.466 
 Range 0-270 0-246 - 
Histologyc AC 407 (39%) - - 
 SCC 373 (36%) - - 
 Other 260 (25%) - - 
Tumour Stagec I 422 (40.6%) - - 
 II 202 (19.4%) - - 
 III 231 (22.2%) - - 
 IV 113 (10.8%) - - 
 Unknown 72 (7%) -  
 
aSubjects with COPD were combined with healthy smokers to form the control group 
bLevel of significance (α) was considered to be 0.05, χ2 or t-test, cases versus all controls 
cPresented as number (%) 
dPack-years (a measure of cumulative smoking exposure) was defined as the average number of packs (20 





Table 2: Hardy-Weinberg chi-square tests for NSCLC and controls.   
 PCR-RFLP Sequenom IPLEX 




CYP1A1*2A 0.16 0.45 0.04 0.51 
CYP1A1*2C 0.03 0.01 0.34 0.07 
CYP1A1*4 0.48 0.27 0.96 0.18 
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